Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,370.00
Bid: 12,370.00
Ask: 12,374.00
Change: 38.00 (0.31%)
Spread: 4.00 (0.032%)
Open: 12,350.00
High: 12,432.00
Low: 12,314.00
Prev. Close: 12,332.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Sterling back above $1.37, helped by dollar turnaround

Thu, 28th Jan 2021 12:23

* Graphic: World FX rates in 2020 http://tmsnrt.rs/2egbfVh

* Graphic: Trade-weighted sterling since Brexit vote http://tmsnrt.rs/2hwV9Hv
(Updates prices, adds detail)

By Elizabeth Howcroft

LONDON, Jan 28 (Reuters) - The pound staged a temporary
retreat on Thursday as investors tempered some of their optimism
about Britain's vaccine rollout, but a weaker dollar later
helped it return above $1.37.

Sterling hit its highest level against the dollar since May
2018 on Wednesday and later reached an eight-month high against
the euro, a move analysts attributed to Britain rolling out
COVID-19 vaccines faster than continental Europe.

Concern about vaccine rollouts globally, and the impact of
mutations of the coronavirus, created a cautious tone in
markets, and a stronger dollar, which meant that the British
currency eased off these highs on Thursday.

But the dollar weakened at around 1340 GMT, with Wall Street
equities rallying, causing cable to head back towards its highs.

At 1626 GMT, the pound was up 0.2% against the dollar, at
$1.3724, compared with Wednesday's $1.3759 high.

Versus the euro, it was up around 0.2% at 88.345 pence,
after peaking at 88.135 in the previous session.

"We consider sterling optimism to be excessive and we see
the risk of disappointed expectations," Commerzbank FX
strategist You-Na Park-Heger wrote in a note to clients.

"The markets are clearly ignoring that the current infection
situation in the UK is still very tense," she said.

Britain has the world's fifth highest death toll from
COVID-19, and Prime Minister Boris Johnson has indicated that a
strict lockdown in England will last until March 8.

British households have cut debit and credit card spending
sharply and the proportion of workers on furlough has risen to
its highest since July.

Britain said it must get all the COVID-19 vaccines it had
ordered and paid for, after some European Union politicians
asked drugmaker AstraZeneca to divert doses from the UK to make
up for a shortfall in supplies.

Elsewhere, British officials told Reuters that the country
will submit a request to join a trans-Pacific trading bloc
grouping 11 countries before it has published an assessment of
the benefits of membership.
(Reporting by Elizabeth Howcroft; Editing by William Maclean,
Larry King and Alexander Smith)

More News
Today 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.